Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome
ACS Medicinal Chemistry Letters August 15, 2025 DOI: 10.1021/acsmedchemlett.5c00475 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin Serotonin |
| Keywords | Agonism Hallucinogen Divergence linguistics 5-HT Receptor Psychotherapist Pharmacology |
| Key findings | Structural modifications of phenalkylamines and tryptamines can yield functional selectivity at 5-HT receptors, reducing hallucinogenic risk while preserving therapeutic efficacy for demoralization syndrome and depression-related conditions. |
Abstract
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as rational therapeutics for demoralization syndrome and depression-related conditions.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cites 3
- Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology September 15, 2022
- Utilizing Psychedelics to Enhance Well-Being: A Systematic Review Journal of Psychoactive Drugs March 31, 2025
- Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes Neuropharmacology March 7, 2025